Methotrexate chronotherapy is effective against rheumatoid arthritis

Chronobiology International

Volumn 28, Issue 3, 2011, Pages 267-274

  To, Hideto ^a   Yoshimatsu, Hiromichi ^b   Tomonari, Mari ^d   Ida, Hiroaki ^e,f   Tsurumoto, Toshiyuki ^g   Tsuji, Yasuhiro ^h   Sonemoto, Emi ^h   Shimasaki, Noriko ^d   Koyanagi, Satoru ^c   Sasaki, Hitoshi ^d   Ieiri, Ichiro ^b   Higuchi, Shun ^b   Kawakami, Atsushi ^f   Ueki, Yukitaka ^h   Eguchi, Katsumi ^f  

^a UNIVERSITY OF TOYAMA   (Japan)

^b Clinical Pharmacokinetics ^*  (Japan)

^c KYUSHU UNIVERSITY   (Japan)

^d NAGASAKI UNIVERSITY HOSPITAL   (Japan)

^e KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f Unit of Translational Medicine   (Japan)

^g NAGASAKI UNIVERSITY   (Japan)

^h SASEBO CHUO HOSPITAL   (Japan)

Author keywords

Chronotherapy; Human trials; Ig GRF; Methotrexate; Rheumatoid arthritis; Rodent models; Serum Amyloid A; TNF

Indexed keywords

IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENT; MESSENGER RNA; METHOTREXATE; RHEUMATOID FACTOR; SERUM AMYLOID A; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANIMAL; ARTICLE; CHRONOTHERAPY; CIRCADIAN RHYTHM; CLINICAL TRIAL; GENETICS; HUMAN; LEUKOCYTE; MALE; METABOLISM; MOUSE; MURPHY ROTHS LARGE LYMPHOPROLIFERATIVE MOUSE; RHEUMATOID ARTHRITIS;

ADULT; ANIMALS; ARTHRITIS, RHEUMATOID; CHRONOTHERAPY; CIRCADIAN RHYTHM; DRUG CHRONOTHERAPY; HUMANS; IMMUNOGLOBULIN G; IMMUNOSUPPRESSIVE AGENTS; LEUKOCYTES; MALE; METHOTREXATE; MICE; MICE, INBRED MRL LPR; RHEUMATOID FACTOR; RNA, MESSENGER; SERUM AMYLOID A PROTEIN; TUMOR NECROSIS FACTOR-ALPHA; YOUNG ADULT;

ANIMALIA; MUS; RODENTIA;

EID: 79953653530     PISSN: 07420528     EISSN: 15256073     Source Type: Journal    
DOI: 10.3109/07420528.2011.553017     Document Type: Article

References (40)

1. Abe C, Mitsunaga K, Shiokawa Y. (1980). Spontaneous polyarthritis in MRL/l mice. Ryumachi 20:233-239.
2. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, Cooper NS. (1988). The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum. 31:315-324. (Pubitemid 18091653)
3. Arvidson NG, Gudbjornsson B, Larsson A, Hallgren R. (1997). The timing of glucocorticoid administration in rheumatoid arthritis. Ann. Rheum. Dis. 56:27-31. (Pubitemid 27060569)
4. Balis FM, Jeffries SL, Lange B, Murphy RF, Doherty KM, Arndt CA, Luery N, Poplack DG. (1989). Chronopharmacokinetics of oral methotrexate and 6-mercaptopurine: is there diurnal variation in the disposition of antileukemic therapy? Am. J. Pediatr. Hematol. Oncol. 11:324-326. (Pubitemid 19213454)
5. Becker C, Barbulescu K, Hildner K, Meyer zum Büschenfelde KH, Neurath MF. (1998). Activation and methotrexate-mediated suppression of the TNFα promoter in T cells and macrophages. Ann. N. Y. Acad. Sci. 859:219-222. (Pubitemid 29021028)
6. Bellamy N, Sothern RB, Campbell J, Buchanan WW. (1991). Circadian rhythm in pain, stiffness, and manual dexterity in rheumatoid ar-thritis: relation between discomfort and disability. Ann. Rheum. Dis. 50:243-248.
7. Bellamy N, Sothern RB, Campbell J, Buchanan WW. (2002). Rhythmic variations in pain, stiffness, and manual dexterity in hand osteoar-thritis. Ann. Rheum. Dis. 61:1075-1080. (Pubitemid 35397354)
8. Buttgereit F, Doering G, Schaeffler A, Witte S, Sierakowski S, Gromnica-Ihle E. (2008). Efficacy of modified-release versus standard predni-sone to reduce duration of morning stiffness of the joints in rheu-matoid arthritis (CAPRA-1): a double-blind, randomised controlled trial. Lancet 371:205-214.
9. Carpentier N, BertinP, Marquet P, Sabot C, Bonnet C, Debord J, Lachâ-tre G, Trèves R. (1998). Is there an optimal time to administer meth-otrexate in the treatment of rheumatoid arthritis? J. Rheumatol. 25:1270-1275. (Pubitemid 28312341)
10. Choi HK, Hernán MA, Seeger JD, Robins JM, Wolfe F. (2002). Metho-trexate and mortality in patients with rheumatoid arthritis: a pro-spective study. Lancet359:1173-1177. (Pubitemid 34304256)
11. Chu CQ, Field M, Feldmann M, Maini RN. (1991). Localization of tumor necrosis factor alpha in synovial tissues and at the carti-lage-pannus junction in patients with rheumatoid arthritis. ArthritisRheum. 34:1125-1132.
12. Cohen S, Cannon GW, Schiff M, Weaver A, Fox R, Olsen N, Furst D, Sharp J, Moreland L, Caldwell J, Kaine J, Strand V. (2001). Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrex-ate. ArthritisRheum. 44:1984-1992. (Pubitemid 33644039)
13. Crofford LJ, Kalogeras KT, Mastorakos G, Magiakou MA, Wells J, Kanik KS, Gold PW, Chrousos GP, Wilder RL. (1997). Circadian relationships between interleukin (IL)-6 and hypothalamic-pitu-itary-adrenal axis hormones: failure of IL-6 to cause sustained hypercortisolism in patients with early untreated rheumatoid ar-thritis. J. Clin. Endocrinol. Metab. 82:1279-1283. (Pubitemid 27166676)
14. DAlonzo GE, Smolensky MH, Feldman S, Gnosspelius Y, Karlsson K. (1995). Bambuterol in the treatment of asthma: a placebo-con-trolled comparison of once-daily morning vs. evening adminis-tration. Chest 107:406-412.
15. Fransen J, van Riel PL. (2005). The Disease Activity Score and the EULAR response criteria. Clin. Exp. Rheumatol. 23:S93-S99. (Pubitemid 46657516)
16. Haus E. (2007). Chronobiology in the endocrine system. Adv. Drug Deliv. Rev. 59:985-1014. (Pubitemid 47531900)
17. Hermida RC, Ayala DE, Mojón Fernández JR. (2010). Influence of cir-cadian time of hypertension treatment on cardiovascular risk: results of the MAPEC Study. Chronobiol. Int. 27:1629-1651.
18. Herold M, Günther R. (1987). Circadian rhythm of C-reactive protein in patients with rheumatoid arthritis. Prog. Clin. Biol. Res. 227B:271-279.
19. Kodama A, To H, Kinoshita T, Ieiri I, Higuchi S. (2009). Influence of dosing schedules on toxicity and antitumour effects of combined cisplatin and docetaxel treatment in mice. J. Pharm. Pharmacol. 61:615-621.
20. Koopman WJ, Gay S. (1988). The MRL-lpr/lpr mouse. A model for the study of rheumatoid arthritis. Scand. J. Rheumatol. 75 (Suppl):284-289.
21. Kowanko IC, Knapp MS, Pownall R, Swannell AJ. (1982). Domiciliary self-measurement in rheumatoid arthritis and the demonstration of circadian rhythmicity. Ann. Rheum. Dis. 41:453-455. (Pubitemid 12035488)
22. Kremer JM, Phelps CT. (1992). Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of90 months. ArthritisRheum. 35:138-145.
23. Lévi F, Zidani R, Misset JL. (1997). Randomised multicentre trial of chronotherapy with oxaliplatin, fluorouracil, and folinic acid in metastatic colorectal cancer. Lancet 350:681-686. (Pubitemid 27371165)
24. Marinova-Mutafchieva L, Williams RO, Mason LJ, Mauri C, Feldmann M, Maini RN. (1997). Dynamics of proinflammatory cytokine expression in the joints of mice with collagen-induced arthritis (CIA). Clin. Exp. Immunol. 107:507-512. (Pubitemid 27102139)
25. Mussener A, Litton MJ, Lindroos E, Klareskog L. (1997). Cytokine production in synovial tissue of mice with collagen-induced arthritis (CIA). Clin. Exp. Immunol. 107:485-493. (Pubitemid 27102136)
26. Ohdo S, Inoue K, Yukawa E, Higuchi S, Nakano S, Ogawa N. (1997). Chronotoxicity of methotrexate in mice and its relation to circadian rhythm of DNA synthesis and pharmacokinetics. Jpn. J. Pharmacol. 75:283-290. (Pubitemid 28000173)
27. Perry MG, Kirwan JR, Jessop DS, Hunt LP. (2009). Overnight variations in cortisol, interleukin 6, tumour necrosis factor α and other cytokines in people with rheumatoid arthritis. Ann. Rheum. Dis. 68:63-68.
28. Pincus T, Summey JA, Soraci SA, Wallston KA, Hummon NP. (1983). Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire. ArthritisRheum. 26:1346-1353. (Pubitemid 14231480)
29. Portaluppi F, Smolensky MH, Touitou Y. (2010). Ethics and methods for biological rhythm research on animals and human beings. Chronobiol. Int. 27:1911-1929.
30. Rivard GE, Infante-Rivard C, Dresse MF, Leclerc JM, Champagne J. (1993). Circadian time-dependent response of childhood lymphoblastic leukemia to chemotherapy: a long-term follow-up study of survival. Chronobiol. Int. 10:201-204. (Pubitemid 23185015)
31. Robinson BA, Begg EJ, Colls BM, Jeffery GM, Sharman JR. (1989). Circadian pharmacokinetics of methotrexate. Cancer Chemother. Pharmacol. 24:397-399. (Pubitemid 19239322)
32. Saito Y, Yoshida S, Nakaya N, Hata Y, Goto Y. (1991). Comparison between morning and evening doses of simvastatin in hyperlipidemic subjects. A double-blind comparative study. Arterioscler. Thromb. 11:816-826.
33. SchmiegelowK, GlomsteinA, KristinssonJ, SalmiT, SchrøderH, Björk O. (1997). Impact of morning versus evening schedule for oral methotrexate and 6-mercaptopurine on relapse risk for children with acute lymphoblastic leukemia. Nordic Society for Pediatric Hematology and Oncology (NOPHO). J. Pediatr. Hematol. Oncol. 19:102-109. (Pubitemid 27200551)
34. Smolensky MH, Lemmer B, Reinberg AE. (2007). Chronobiology and chronotherapy of allergic disease and bronchial asthma. Adv. DrugDeliv. Rev. 59:828-851.
35. Sulli A, Maestroni GJ, Villaggio B, Hertens E, Craviotto C, Pizzorni C. (2002). Melatonin serum levels in rheumatoid arthritis. Ann. N. Y. Acad. Sci. 966:276-283. (Pubitemid 34729186)
36. Tabuchi M, To H, Sakaguchi H, Goto N, Takeuchi A, Higuchi S, Ohdo S. (2005). Therapeutic index by combination of adriamycin and docetaxel depends on dosing time in mice. Cancer Res. 65:8448-8454. (Pubitemid 41330612)
37. To H, Irie S, Tomonari M, Watanabe Y, Kitahara T, Sasaki H. (2009). Therapeutic index of methotrexate depends on circadian cycling of tumor necrosis factor-α in collagen-induced arthritis rats and mice. J. Pharm. Pharmacol. 61:1333-1338.
38. van Gestel AM, Prevoo ML, van 't Hof MA, van Rijswijk MH, van de Putte LB, van Riel PL. (1996). Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum. 39:34-40. (Pubitemid 26036375)
39. Weinblatt ME, Weissman BN, Holdsworth DE, Fraser PA, Maier AL, Falchuk KR, Coblyn JS. (1992). Long-term prospective study of methotrexate in the treatment of rheumatoid arthritis. 84-month update. ArthritisRheum. 35:129-137.
40. Williams AS, Topley N, Dojcinov S, Richards PJ, Williams BD. (2001). Amelioration of rat antigen-induced arthritis by liposomally conjugated methotrexate is accompanied by down-regulation ofcytokine mRNA expression. Rheumatology 40:375-383.